noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Celcuity Inc.

A Phase 3 study of gedatolisib plus fulvestrant with and without[...]
Celcuity Inc.

Gedatolisib, a well tolerated pan PI3K/mTOR inhibitor, exhibits potent[...]
Celcuity Inc.

Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency &[...]

Healthcare

Celcuity Inc.

05/09/2023 | Press release | Archived content

Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment naïve patients

Sharing and Personal Tools

Please select the service you want to use: